View:

Download DOC

Download PDF

Download XLS

EDAP TMS S.A. REPORTS 2002 FIRST QUARTER FINANCIAL RESULTS
- Strong European Acceptance of Ablatherm -
- Substantial Backlog for Core Lithotripsy Products -

Vaulx-en-Velin, France, May 15, 2002 - EDAP TMS S.A. (Nasdaq: EDAP), a global leader in the development, marketing and distribution of a portfolio of minimally-invasive medical devices for the treatment of urological diseases, today reported financial results for the first quarter ended March 31, 2002.

EDAP TMS S.A. reported total revenues of EUR 5.1 million (USD 4.4 million) for the first quarter of 2002, compared to EUR 5.7 million (USD 5.2 million) for the first quarter 2001. Net sales were EUR 5.0 million (USD 4.3 million) compared to EUR 5.6 million (USD 5.1 million) for the same period a year earlier. The Company attributed the decline in revenues and net sales to the impact of transferring certain TUMT related manufacturing to Urologix in August of 2001.

Gross profit was EUR 2.2 million (USD 1.9 million) as compared to EUR 2.4 million (USD 2.2 million) in the first quarter of 2001. The Company reported an operating loss for the three months ended March 31, 2002, of EUR 0.7 million (USD 0.6 million), compared to a loss of EUR 0.3 million (USD 0.3 million) for the three months ending March 31, 2001. The Company recorded a net profit of EUR 1.2 million (USD 1.0 million) or EUR 0.14 per diluted share (USD 0.12), as compared with a net profit of EUR 0.2 million (USD 0.2 million) or EUR 0.02 per diluted share (USD 0.02), for the same quarter of the prior year. The net profit for the quarter is directly attributable to income generated from the sale of common stock acquired in connection with the sale of the TUMT division.

Eric Simon, EDAP's Chief Executive Officer, commented, "Our results in the first quarter of 2002 are in line with our expectations and we believe that it places the Company in a good position to meet the guidance we provided during our 2001 fiscal year end report. At that time, we stated that in 2002 the Company expects to double our 2001 Ablatherm related revenues of EUR 1.6 million. In this quarter, we generated EUR 1.2 million related to our HIFU business, including the sale of two units in Europe. To date, the acceptance and recognition of Ablatherm in Europe has been very successful.

"Our total lithotripsy business, including the sale of four units during the quarter, contributed EUR 3.2 million to our total revenues. This business has a substantial backlog which is scheduled to be delivered over the balance of the year and includes our first Sonolith Praktis order in the United States.

"Finally, as a follow-up to the status of the Ablatherm primary protocol, after an initial meeting with a representative of the AUA, and prior to the Company's meeting with the FDA we are optimistic that the FDA will be receptive to a resubmission of a protocol that is acceptable to the Company," concluded Mr. Simon.

Separately, the Company announced that it will be exhibiting this year at the AUA meeting in Orlando, Florida beginning on May 26, 2002. Representatives of EDAP will be available at the Company's booth (Booth #821) to meet with interested parties and review the product lines.

EDAP TMS S.A., is the global leader in the development, production, marketing and distribution of a portfolio of minimally invasive medical devices primarily for the treatment of urological diseases. The Company currently produces and markets devices for the minimally invasive treatment of localized prostate cancer, using High Intensity Focused Ultrasound (HIFU) and the treatment of urinary tract stones using Extra-corporeal Shockwave Lithotripsy (ESWL). The Company also produces and markets in Japan and Italy devices for the non-surgical treatment of benign Prostate Hyperplasia (BPH) using Microwave Thermotherapy (TUMT). The Company is also developing HIFU for the treatment of certain other types of tumors. For more information, in the U.S., contact EDAP Technomed Inc., the Company's U.S. subsidiary located in Atlanta, GA, by phone at (770) 446-9950.

This press release contains, in addition to historical information, forward-looking statements that involve risks and uncertainties. These include statements regarding the Company's growth and expansion plans. Such statements are based on management's current expectations and are subject to a number of uncertainties and risks that could cause actual results to differ materially from those described in the forward-looking statements. Factors that may cause such a difference include, but are not limited to, those described in the Company's filings with the Securities and Exchange Commission.

NOTE: Translated for convenience of the reader to U.S. dollars at the year 2002 average three months noon buying rate of 1 Euro = 0.8656 USD, and year 2001 average three months noon buying rate of 1 Euro = 0.9105 USD.

NOTE: Translated for convenience of the reader to U.S. dollars at the noon buying rate of 1 Euro = 0.8717 USD, on March 31, 2002 and at the noon buying rate of 1 Euro = 0.8901 USD, on December 31, 2001.